Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Ehrreich

Pediatrics Madera, CA Medical Doctor

NPI 1780651893 CMS profile 126501

9300 Valley Childrens Pl, Madera, CA 93638

Open in the dashboard

General payments

$58,542

593 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Ehrreich of Madera, CA is reported in the CMS Open Payments database as having received $58,542 across 593 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,113 126
2024 General $8,143 91
2023 General $9,416 80
2022 General $15,765 94
2021 General $2,750 47
2020 General $1,214 42
2019 General $4,141 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Ehrreich
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Steven Ehrreich were reported at $17,113. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Steven Ehrreich Pediatrics median Middle half National median
2019 $4,141 $86 $31–$183 $163
2020 $1,214 $49 $22–$110 $114
2021 $2,750 $68 $27–$158 $132
2022 $15,765 $77 $30–$173 $149
2023 $9,416 $88 $33–$190 $160
2024 $8,143 $94 $34–$206 $164
2025 $17,113 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $32,122 76 payments
  2. Catalyst Pharmaceuticals, Inc. $6,179 29 payments
  3. Marinus Pharmaceuticals, Inc. $4,056 21 payments
  4. NeuroPace, Inc. $3,421 29 payments
  5. Zogenix Inc. $1,670 11 payments
  6. UCB, Inc. $1,665 62 payments
  7. LivaNova USA, Inc. $1,228 36 payments
  8. Neurelis, Inc. $1,068 34 payments
  9. Greenwich Biosciences, Inc. $838 26 payments
  10. Alexion Pharmaceuticals, Inc. $546 14 payments
  11. Other $5,750 255 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25,242 13 payments
  2. Food and Beverage $17,397 562 payments
  3. Consulting Fee $6,020 2 payments
  4. Travel and Lodging $5,883 15 payments
  5. Honoraria $4,000 1 payment
Products named General payments · program years 2019–2025
  1. Epidiolex $32,754 99 payments
  2. FYCOMPA $5,900 19 payments
  3. ZTALMY $4,056 21 payments
  4. RNS System $1,834 12 payments
  5. Fintepla Treatment of seizures $1,670 11 payments
  6. RNS Neurostimulator Kit $1,429 15 payments
  7. VALTOCO $1,068 34 payments
  8. VNS Therapy $810 21 payments
  9. Fintepla Neurology $788 28 payments
  10. Briviact $477 25 payments
  11. Other $6,990 293 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

76

Median for Pediatric Medicine: 38

Drug cost

$30,192

Median for Pediatric Medicine: $2,769

Branded share of claims

44.7%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lamictal Odt Lamotrigine Brand 23 $20,743
Keppra Levetiracetam Brand 11 $6,862
Clobazam Generic 11 $1,146
Levetiracetam Generic 14 $886
Lamotrigine Generic 17 $555

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $3,489
$3,489 — —
ZTALMY
  • Marinus Pharmaceuticals, Inc. $1,680
$1,680 — —
VALTOCO
  • Neurelis, Inc. $331
$331 — —
Fintepla
  • UCB, Inc. $166
$166 — —
FYCOMPA
  • CATALYST PHARMACEUTICALS, INC. $157
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

593 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record